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Ubiquitin-dependent proteolysis in
yeast cells expressing neurotoxic
proteins
Ralf J. Braun ∗
Institut für Zellbiologie, Universität Bayreuth, Bayreuth, Germany
Critically impaired protein degradation is discussed to contribute to neurodegenerative
disorders, including Parkinson’s, Huntington’s, Alzheimer’s, and motor neuron diseases.
Misfolded, aggregated, or surplus proteins are efficiently degraded via distinct protein
degradation pathways, including the ubiquitin-proteasome system, autophagy, and
vesicular trafficking. These pathways are regulated by covalent modification of target
proteins with the small protein ubiquitin and are evolutionary highly conserved from
humans to yeast. The yeast Saccharomyces cerevisiae is an established model for
deciphering mechanisms of protein degradation, and for the elucidation of pathways
underlying programmed cell death. The expression of human neurotoxic proteins triggers
cell death in yeast, with neurotoxic protein-specific differences. Therefore, yeast cell death
models are suitable for analyzing the role of protein degradation pathways in modulating
cell death upon expression of disease-causing proteins. This review summarizes which
protein degradation pathways are affected in these yeast models, and how they are
involved in the execution of cell death. I will discuss to which extent this mimics
the situation in other neurotoxic models, and how this may contribute to a better
understanding of human disorders.
Keywords: ubiquitylation, ubiquitin-proteasome system, autophagy, ubiquitin-dependent vesicular trafficking,
neurodegeneration, cell death, Saccharomyces cerevisiae
Introduction
Ubiquitin is a highly conserved protein with 76 amino acids (Weissman et al., 2011; Finley
et al., 2012). It is covalently linked to lysine side chains of substrate proteins by the sequen-
tial action of the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzymes (E2), and
substrate-specific ubiquitin ligases (E3) (Weissman et al., 2011; Finley et al., 2012). Deubiq-
uitylating enzymes (DUBs) recycle ubiquitin, replenishing the cellular pool of free ubiquitin.
The high variety of ubiquitin modifications, including mono- and polyubiquitylations, destines
the degradation, localization, and/or function of substrate proteins. Consequently, numerous
cellular processes are regulated by ubiquitylation, including protein degradation, cell death control,
Abbreviations: AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; DUB, Deubiquitylating enzyme; ERAD,
ER-associated degradation; HD, Huntington’s disease; IPOD, Insoluble protein deposit/ perivacuolar aggregates; MAD,
Mitochondrion-associated degradation; MVB, Multivesicular bodies; PD, Parkinson’s disease; polyQ, Proteins with abnormal
glutamine expansions; ROS, Reactive oxygen species; UFD, Ubiquitin-fusion degradation pathway; UPR, Unfolded protein
response; UPS, Ubiquitin-proteasome system.
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and vesicular trafficking (Weissman et al., 2011; Finley et al.,
2012). These ubiquitin-dependent processes are highly conserved
from yeast to humans (Finley et al., 2012).
Polyubiquitylated proteins are degraded within the protea-
some, a cylindrical multiprotein complex with chymotrypsin-,
trypsin-, and caspase-like proteolytic activities. This ubiquitin-
dependent degradation of proteins via the proteasome is called
the ubiquitin-proteasome system (UPS) (Weissman et al., 2011;
Finley et al., 2012). The ubiquitylation of many plasma mem-
brane proteins promotes their targeting into endosomes and
multivesicular bodies (MVB) leading to their degradation by
multiple proteases in the lysosomes (or vacuoles in yeast) (Fin-
ley et al., 2012; MacGurn et al., 2012). This MVB pathway of
protein degradation (also called endosomal-lysosomal pathway)
is a ubiquitin-controlled vesicle-based protein degradation path-
way, which is independent from proteasomes. Ubiquitylation can
also be involved in the degradation of substrate proteins via
autophagy (Kuang et al., 2013; Lu et al., 2014). Autophagy is a
cellular process where proteins, protein aggregates, or organelles
are enclosed by a double membrane forming autophagosomes,
which eventually fuse with lysosomes (vacuoles) for degradation.
One mechanism to ensure specificity during autophagy relies on
the ubiquitylation of target proteins or organelles and the conse-
quent use of specific adaptors that connect the ubiquitin system
with the autophagy pathway (Kuang et al., 2013; Lu et al., 2014).
The UPS, the MVB pathway, and autophagy share some com-
ponents, such as the AAA-ATPase p97/VCP (or Cdc48 in yeast)
(Bug and Meyer, 2012; Dargemont and Ossareh-Nazari, 2012),
and the E3 ligase Nedd4 (or Rsp5 in yeast) (MacGurn et al., 2012;
Fang et al., 2014; Lu et al., 2014), making these proteins to poten-
tial key players that decide by which pathway a protein is to be
degraded.
Accumulation of aggregated proteins is a common hallmark
of many neurodegenerative disorders, and believed to con-
tribute to neuronal dysfunction (Lansbury and Lashuel, 2006).
In Parkinson’s disease (PD) cytoplasmic Lewy bodies are pro-
tein aggregates mainly comprised by the protein α-synuclein
(Uversky, 2007), and nuclear protein aggregates of the polyg-
lutamine protein hungtingtin are typical for Huntington’s dis-
ease (HD) (Ross and Tabrizi, 2011). In Alzheimer’s disease
(AD) the hydrophobic peptide β-amyloid is produced in cells
but accumulates in extracellular plaques (Laferla et al., 2007).
The microtubule-associated protein tau (MAPT), and UBB+1,
the frameshift variant of human ubiquitin B, is enriched in
intracellular inclusions during AD (van Leeuwen et al., 1998;
Mandelkow and Mandelkow, 2012). Accumulation of cytoplas-
mic aggregates of disease-causing proteins, such as TDP-43
or FUS/TLS, occurs during the motor neuron disease amy-
otrophic lateral sclerosis (ALS) (Andersen and Al-Chalabi, 2011).
Most of these disease-associated proteins or aggregates are
ubiquitylated. Therefore, the observed accumulation of pro-
tein aggregates has been explained by dysfunctional protein
degradation pathways, including the UPS and autophagy (Den-
nissen et al., 2012; Dantuma and Bott, 2014). However, the
precise role of ubiquitin-dependent proteolysis and its impor-
tance for the progression of the human disorders remains poorly
understood.
Yeast is an established model for measuring cytotoxicity and
programmed cell death, and for dissecting conserved mech-
anisms of apoptosis and necrosis (Carmona-Gutierrez et al.,
2010). Diverse roles of ubiquitin-dependent protein degrada-
tion have been described in distinct yeast cell death scenarios.
The ubiquitin-dependent and proteasome-independent routing
of misfolded proteins to the MVB pathway for their degrada-
tion protects cells from cytotoxicity (Wang et al., 2011). Elevated
proteasome capacity extends the replicative life span and fit-
ness of yeast cells, which are more resistant against proteotoxic
stress (Kruegel et al., 2011). Decreased proteasome capacity
by proteasome inhibition leads to disturbances in the amino
acid homeostasis, thereby executing cell death (Suraweera et al.,
2012). Impairment of distinct branches of the UPS pathway,
including the ER- and the mitochondrion-associated degradation
(ERAD/MAD) are sufficient to trigger cell death in yeast, empha-
sizing their cytoprotective role in the homeostasis of the ER and
mitochondria (Braun et al., 2006; Zischka et al., 2006; Heo et al.,
2010). However, UPS impairment (due to proteasome inhibition)
can also prevent from cell death, e.g., when cell death is triggered
by acetic acid and the chemotherapeutic drug cisplatin, respec-
tively (Valenti et al., 2008; Cunha et al., 2013). Thus, ubiquitin-
dependent proteolysis is involved in both the execution of and
the prevention from yeast cell death.
In recent years, many yeast models have been established to
analyze the influence of human neurotoxic protein expression
on yeast cell survival, including models for PD, HD, AD, and
ALS (Gitler, 2008; Miller-Fleming et al., 2008; Winderickx et al.,
2008; Bharadwaj et al., 2010; Braun et al., 2010; Khurana and
Lindquist, 2010; Bastow et al., 2011; Mason and Giorgini, 2011).
Here, I summarize how ubiquitin-dependent protein degradation
is impaired in yeast cell death models expressing neurotoxic pro-
teins, and which role proteolysis plays in the execution of cell
death. Further, I will discuss some similarities between the yeast
models expressing neurotoxic proteins, and the animal and cell
culture disease models.
Yeast Models Expressing Neurotoxic
Proteins
Parkinson’s Disease (PD)
PD is the most prevalent age-related movement disorder char-
acterized by a progressive loss of dopaminergic neurons in the
substantia nigra, leading to the impairment of normal motor
function culminating in resting tremor, bradykinesia and rigid-
ity (Lees et al., 2009). In most familiar and sporadic cases, PD is
associated with Lewy bodies, i.e., intracellular cytoplasmic aggre-
gates composed of the protein α-synuclein (Uversky, 2007). Mis-
sense mutations in the SNCA gene, resulting in the expression
of α-synuclein variants (A18T, A29S, A30P, A53T, E46K, H50Q,
G51D), as well as duplication and triplication of SNCA, lead-
ing to elevated α-synuclein levels, are causative for PD in some
familiar forms of the disorder (Fujioka et al., 2014). Numerous
α-synuclein disease models expressing wild-type and disease-
associated variants have been established, including several yeast
models.
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In Yeast, α-Synuclein is a Membrane-Associated
Protein, which is Degraded Via the UPS, Autophagy,
and Potentially the MVB Pathway
When expressed in yeast, α-synuclein binds to vesicles of the
secretory pathway, leading to its localization to the plasma mem-
brane (Outeiro and Lindquist, 2003; Dixon et al., 2005; Sharma
et al., 2006; Zabrocki et al., 2008). This depends on α-synuclein
phosphorylation (Basso et al., 2013; Tenreiro et al., 2014), and
can be interrupted by genetic manipulation (e.g., α-synuclein-
A30P) (Outeiro and Lindquist, 2003; Dixon et al., 2005; Sharma
et al., 2006). Upon high expression levels α-synuclein forms
cellular aggregates in a nucleation-dependent manner, which
starts at the plasma membrane and eventually leads to cyto-
plasmic inclusions (Outeiro and Lindquist, 2003). These inclu-
sions co-localize with markers of different vesicles, including
Ypt1 (ER-to-Golgi), Ypt31 (late Golgi), Sec4 (secretory vesicles-
to-plasma membrane), Ypt6 (endosome-to-Golgi), Vps21 and
Ypt52 (early-to-late endosome) and Ypt7 (late endosome-to-
vacuole) (Gitler et al., 2008). Thus, α-synuclein is an aggregation-
prone membrane-associated protein.
Although α-synuclein is ubiquitylated in yeast (Outeiro and
Lindquist, 2003), to which extent the UPS contributes to its
degradation in human cells (Xilouri et al., 2013) or more specif-
ically in yeast (see below), remains an open debate. Treat-
ment of yeast cells expressing α-synuclein with the proteasome
inhibitor lactacystin resulted in increased α-synuclein aggrega-
tion (Zabrocki et al., 2005; Lee et al., 2008). Consistently, expres-
sion of α-synuclein in the yeast strain sen3-1, which harbors a
mutation in the gene encoding the regulatory proteasome sub-
unit Rpn2, led to increased steady-state levels of α-synuclein
(using untagged α-synuclein) and to increased formation of
aggregates (using GFP-tagged α-synuclein) (Sharma et al., 2006).
These data suggest that α-synuclein is a UPS substrate in
yeast.
In other studies with yeast cells expressing GFP-tagged α-
synuclein, α-synuclein aggregate clearance was neither affected
by treatment with the proteasome inhibitor MG132 (Petroi et al.,
2012; Tenreiro et al., 2014), nor by mutation in the gene encod-
ing the regulatory proteasome subunit Rpt6 (cim3-1) (Petroi
et al., 2012). Further, the steady-state levels of α-synuclein were
not affected by MG132 treatment (Tenreiro et al., 2014). These
data argue against the contribution of the UPS in α-synuclein
degradation in yeast. Here, α-synuclein aggregate clearance was
dependent on autophagy and vacuolar protease activity. Treat-
ment of yeast cells expressing α-synuclein-GFP with the protease
inhibitor phenylmethylsulfonyl fluoride (PMSF), an inhibitor of
vacuolar proteases, resulted in a significant reduction of this
clearance (Petroi et al., 2012). Similarly, genetic interruption of
autophagy (1atg1 or 1atg7) delayed aggregate clearance (Petroi
et al., 2012; Tenreiro et al., 2014), and increased the steady-state
levels of α-synuclein (1atg7) (Tenreiro et al., 2014). Consistently,
inducing autophagy by rapamycin promoted aggregate removal
(Zabrocki et al., 2005), confirming that α-synuclein aggregates
are degraded via autophagy.
Aggregate clearance was not limited to autophagy, because
aggregate clearance still took place in the absence of autophagy
and upon very low UPS activity (cim3-11atg1 strain), suggesting
for an additional cellular clearing mechanism independent from
autophagy and the UPS (Petroi et al., 2012). Indeed, the yeast
E3 ligase Rsp5, and its homolog Nedd4 in mammalian cells, play
critical roles in α-synuclein degradation (Tofaris et al., 2011). In
yeast, α-synuclein was identified as an Rsp5 target for ubiquity-
lation, and upon RSP5 mutation (rsp5-1 strain), both the steady-
state level of α-synuclein, as well as the number of cells showing
α-synuclein aggregation were increased as compared to wild-type
strain (Tofaris et al., 2011). Although Rsp5/Nedd4 is critically
involved in many cellular processes, including theMVB pathway,
ubiquitin-dependent autophagy and the proteasome-dependent
degradation of misfolded proteins (MacGurn et al., 2012; Fang
et al., 2014; Lu et al., 2014), there are some line of evidence sug-
gesting that the MVB pathway contributes to α-synuclein degra-
dation (Tofaris et al., 2011). Mammalian Nedd4 promotes the
degradation of endogenous α-synuclein by lysosomes, and the
targeting of α-synuclein to the lysosomes depends on the endo-
somal sorting complex (ESCRT) (Tofaris et al., 2011). Due to
the high conservation of protein degradation pathways between
mammalian cells and yeast, the critical contribution of Rsp5 in α-
synuclein degradation in yeast might suggest for a potential role
of theMVB pathway in α-synuclein degradation, besides the UPS
and autophagy.
α-Synuclein Expression in Yeast Leads to Impairment
of the UPS, and Vesicular Trafficking
Expression of α-synuclein in yeast leads to UPS impairment. The
protein composition of the proteasome is altered, concomitant to
a moderate decrease in the chymotrypsin-like enzymatic protea-
somal activity (in isolated proteasomes), and to a marked delay
in the degradation of short-lived proteins (pulse-chase assay)
(Chen et al., 2005). Consequently, the cellular levels of polyu-
biquitylated proteins increased moderately (Chen et al., 2005).
The degradation of the UPS model substrate GFPu, in which
the C-terminus of this protein comprises a degron, was delayed
upon α-synuclein expression in yeast (Outeiro and Lindquist,
2003). The impairment of UPS-dependent protein degradation
upon α-synuclein expression appears to be substrate specific.
Whereas, the degradation of the cytosolic proteasome substrate
Deg1-β-Gal was unaffected, the degradation of the ER luminal
substrate CPY* but not of the ER membrane substrate sec61-2
was severely impaired (Cooper et al., 2006). Thus, α-synuclein
expression impairs the UPS andmore specifically the degradation
of selective substrates of the ER-associated degradation (ERAD)
pathway.
α-Synuclein expression also affects vesicular trafficking,
including ER to Golgi transport, endocytosis, vesicular recycling
back to the plasmamembrane, and vacuolar fusion (Cooper et al.,
2006; Gitler et al., 2008; Zabrocki et al., 2008; Basso et al., 2013).
Since theMVB pathway and autophagy depend both on vesicular
fusion processes, it is very likely that α-synuclein expression also
affects the protein degradation via these two vesicle-based path-
ways. Measuring the degradation rates of substrates of autophagy
or the MVB pathway upon α-synuclein expression will help to
address this issue.
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α-Synuclein Expression in Yeast Triggers Cell Death,
which is Modulated by the Activities of the UPS,
Autophagy, and Ubiquitin-Dependent Vesicular
Trafficking
Yeast cells overexpressing wild-type and disease-associated α-
synuclein demonstrated growth deficits and age-dependent loss
of clonogenic cell survival paralleled by the emergence of mor-
phological markers of apoptosis and necrosis (Willingham et al.,
2003; Flower et al., 2005; Witt and Flower, 2006; Büttner et al.,
2008, 2013a,b; Lee et al., 2008; Su et al., 2010). The cellular accu-
mulation of ROS and mitochondrial dysfunction are pivotal for
the execution of α-synuclein-triggered cell death. The use of the
antioxidant N-acetyl cysteine (NAC) or the use of yeast strains
deleted for mitochondrial DNA (ρ0 strain) protected from ROS
and α-synuclein-triggered cell death (Büttner et al., 2008, 2013a).
The translocation of the mitochondrial cell death proteins Nuc1
and cytochrome c, into the nucleus and the cytosol, respectively,
was observed to be critical for the execution of cell death (Flower
et al., 2005; Büttner et al., 2013b). The ER also contributes to cyto-
toxicity, because α-synuclein expression results in ER stress and
in the induction of the unfolded protein response (UPR) (Cooper
et al., 2006).
Since α-synuclein has been proposed to be aUPS substrate and
since α-synuclein expression resulted in UPS impairment (espe-
cially ERAD), it is likely that the UPS is involved in modulating
α-synuclein-triggered cytotoxicity.Moderate α-synuclein expres-
sion, which is non-toxic for wild-type yeast cells, resulted in
severe growth deficits in yeast cells bearing mutations in the 20S
proteasomal barrel (pre1-1001, pre2-1001, doa3-1) (Dixon et al.,
2005; Sharma et al., 2006) and in the 19S regulatory particle of the
26S proteasome (sen3-1) (Sharma et al., 2006), or treated with the
proteasome inhibitor lactacystin (Lee et al., 2008). Consistently,
expression of Rpt5, a component of the 19S regulatory particle,
and expression of the ERAD ubiquitin ligase Hrd1 suppressed α-
synuclein-triggered cytotoxicity (Liang et al., 2008; Gitler et al.,
2009). Bridging high-throughput genetic and transcriptional data
with the ResponseNet algorithm predicted the AAA-ATPase
Cdc48, also critically involved in ERAD, to be a modulator of
α-synuclein-triggered cytotoxicity (Yeger-Lotem et al., 2009).
Thus, the UPS in general, and specifically the ERAD pathway
appears to be a potent modulator of α-synuclein-triggered cell
death.
Since α-synuclein aggregates have been proposed to be sub-
strates of autophagy, it is likely that autophagy, like the UPS,
modulates α-synuclein-triggered cytotoxicity. In fact, the in silico
combination of high-throughput genetic and transcriptional data
predicted the target of rapamycin (TOR) pathway, as amodulator
of α-synuclein-triggered cytotoxicity (Yeger-Lotem et al., 2009).
Addition of the TOR-inhibitor rapamycin markedly enhanced
the growth deficits elicited by α-synuclein (Yeger-Lotem et al.,
2009). Since inactivation of the TOR pathway induces autophagy,
these data suggested, that enhancing autophagy is harmful but
not cytoprotective for cultures expressing α-synuclein. Consis-
tently, pharmacological inhibition of autophagy by treatment
with chloroquine markedly extended chronological life span
of yeast cells expressing α-synuclein (Sampaio-Marques et al.,
2012). Although rapamycin also affects other cellular pathways,
it remains possible that autophagy, in contrast to the UPS, plays
a detrimental role in α-synuclein-triggered cytotoxicity.
Besides the UPS and autophagy, ubiquitin-dependent vesicle
trafficking plays a role in modulating α-synuclein-triggered cyto-
toxicity. The E3 ligase Rsp5, involved in ubiquitin-dependent
vesicle trafficking, was predicted by the ResponseNet algo-
rithm to affect α-synuclein-triggered cytotoxicity (Yeger-Lotem
et al., 2009). Indeed, loss-of-function mutations in the gene
encoding Rsp5 (rsp5-1 strain) increased α-synuclein-triggered
growth deficits, whereas overexpression of Rsp5 was cytopro-
tective (Tofaris et al., 2011). Chemical genetic screens in wild-
type yeast cells established that N-aryl benzimidazole (NAB)
promoted endosomal transport and protected cells from cyto-
toxicity (Tardiff et al., 2013). This was dependent on the deu-
biquitinase Doa4, the E3 ubiquitin ligase Rsp5, the Rsp5 adap-
tor Bul1, the DUBs Ubp7, and Ubp11, which can deubiquity-
late Rsp5 substrates, the potential Rsp5 substrates (Bap2, Bap3,
and Mmp1), and Vps23, which directs Rsp5 substrates for
degradation in the vacuole (Tardiff et al., 2013). Notably, pro-
moting ER-Golgi vesicle trafficking had very similar effects: α-
synuclein-triggered cytotoxicity was reduced, and this reduction
also depended on ubiquitin proteases, namely Ubp3 and its co-
factor Bre5 (Cooper et al., 2006; Gitler et al., 2008). Thus, promot-
ing ubiquitin-regulated vesicle trafficking prevents α-synuclein-
triggered cytotoxicity.
Yeast α-Synuclein Models are Highly Useful to
Elucidate the Role of Diverse Ubiquitin-Related
Protein Degradation Pathways in Modulating
Cytotoxicity and Neuronal Cell Death
In yeast, α-synuclein is both a substrate and an inhibitor for
the UPS, autophagy, and the ubiquitin-dependent vesicular traf-
ficking (Figure 1, Table 1). The activities of the UPS and of
MVB pathways appear to play protective roles, whereas increased
autophagy potentially contribute to α-synuclein-triggered cyto-
toxicity. The relevance of the different pathways in modulating
α-synuclein-triggered cytotoxicity might depend on α-synuclein
itself, e.g., the expression levels, the post-translational modifi-
cations, the cellular localizations, folding or distinct aggrega-
tion conditions. Similarly, the chronological and replicative aging
of the yeast cultures might be decisive. Systematic analyses of
these factors will help to get a better understanding of the
pathophysiological effects of α-synuclein expression in yeast with
respect to the reciprocal effects to ubiquitin-dependent protein
degradation.
These studies are very promising, due to the high consis-
tence of the yeast α-synuclein models with other α-synuclein
model systems. Inmammalian cells, α-synuclein degradation also
depends on the UPS, autophagy, and ubiquitin-dependent vesic-
ular trafficking (more specifically the MVB pathway) (Tofaris
et al., 2011; Ebrahimi-Fakhari et al., 2012; Xilouri et al., 2013).
Likewise, in mammalian cells, α-synuclein interferes with these
ubiquitin-modulated protein degradation pathways, and the
activities of these pathways are discussed to influence the cyto-
toxicity of α-synuclein (Ebrahimi-Fakhari et al., 2012; Xilouri
et al., 2013). Yeast α-synuclein models have already been
very valuable in deciphering novel cellular mechanisms linking
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FIGURE 1 | Yeast model for α-synuclein-triggered cytotoxicity.
α-Synuclein is a plasma membrane- and vesicle-bound protein that upon
high expression levels or upon mutation forms smaller and larger
aggregates, which can be ubiquitylated (1). α-Synuclein can be degraded
via the UPS (2), autophagy (3), and potentially via the MVB pathway (4).
Aggregated α-synuclein triggers mitochondrial dysfunction, ROS, and
mitochondrion-dependent cell death (5), as well as ER stress and the
UPR (6). These cytotoxic effects can at least partially be explained by
α-synuclein-dependent inhibition of the proteasome (7), the ERAD
pathway (8), or vesicular trafficking (9). Impaired vesicular trafficking
includes (but is not limited to) ER-to-Golgi transport, which can be
efficiently restored by Ypt1 expression (10).
ubiquitin-dependent pathways with α-synuclein-triggered cyto-
toxicity. For instance, the influence of the ubiquitin-modulated
ER-Golgi vesicle trafficking on α-synuclein-triggered cytotoxi-
city was first identified in yeast and then confirmed in flies
and worms (Cooper et al., 2006). Likewise, the degradation of
α-synuclein via the MVB pathway is conserved from yeast to
mammalians (Tofaris et al., 2011), and the protective effect of
promoting ubiquitin-dependent endosomal trafficking by NAB
was first identified in yeast and later on confirmed in worms,
rats, and human PD patient-derived neurons (Chung et al., 2013;
Tardiff et al., 2013).
Huntington’s Disease (HD)
HD is an autosomal dominant neurodegenerative disorder char-
acterized by a progressive loss of neurons in the striatum and
the cortex with a consequent decline of cognitive and motor
functions (Ross and Tabrizi, 2011). HD is caused by an abnor-
mal polyglutamine (polyQ) expansion in the protein huntingtin
due to an aberrant CAG codon expansion in the exon 1 of the
gene encoding huntingtin (Ross and Tabrizi, 2011). This results
in an aggregation-prone protein eventually triggering cytotoxic-
ity and neuronal cell loss (Ross and Tabrizi, 2011). Increasing the
length of the polyQ expansion accelerates aggregation of hunt-
ingtin and strictly correlates with the increase in cytotoxicity and
the decrease in disease onset (Ross and Tabrizi, 2011). In order
to dissect underlying mechanisms, various HDmodels have been
established, comprising transgenic mouse lines, mammalian cell
culture, and yeast (Mason and Giorgini, 2011; Ross and Tabrizi,
2011).
In Yeast, Huntingtin with Disease-Associated
Expanded Glutamine Stretches (polyQ) is a
Cytoplasmic Aggregation-Prone Protein, which is
Degraded Via the UPS and Autophagy
In yeast, expression of fluorescence protein-tagged huntingtin
exon 1 with disease-inducing polyQ expansions (e.g., 103Q) led
to very efficient cytoplasmic aggregation, in contrast to fusion
proteins with normal glutamine repeats (e.g., 25Q) (Meriin et al.,
2002, 2003; Duennwald et al., 2006a,b). Intermediate polyQ
length (e.g., 47Q) showed moderate aggregation when expressed
in logarithmically growing cells but here strong aggregation
occurred delayed upon chronological aging (Cohen et al., 2012).
Besides the length of polyQ expansions, aggregation was influ-
enced by the amino acid sequences flanking the polyQ stretch
(Duennwald et al., 2006b; Wang et al., 2009), and by the pres-
ence of endogenous proteins with prion properties and glutamine
repeats (Duennwald et al., 2006a). The N-terminal domain of
huntingtin (N17 fragment) which precedes the polyQ stretch
is required for recruiting the chaperonin TRiC and the 14-3-3
protein Bmh1 which both promote aggregation in yeast and
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cell-free systems (Tam et al., 2009; Wang et al., 2009; Duennwald,
2011; Crick et al., 2013). PolyQ followed by the endogenous
proline-rich region of huntingtin (103QP) tended to form very
tight aggregates (one or two per cell), whereas polyQ lacking the
proline-rich region (103Q) preferred to form amorphous aggre-
gates dispersed throughout the cytosol (Duennwald et al., 2006b).
The yeast protein Rnq1 co-localized with both 103QP and 103Q
aggregates, and its prion conformation [RNQ+] was found to be
necessary for aggregation of 103QP and 103Q (Duennwald et al.,
2006a).
In line with the appearance of different types of polyQ aggre-
gates, these aggregates are directed to at least two cellular com-
partments. First, misfolded polyQ (103QP) was actively trans-
ported to aggresomes (Wang et al., 2009), which are large jux-
tanuclear aggregates that co-localize with the centrosomes in
mammalian cells and the spindle pole bodies in yeast (Johnston
et al., 1998; Wang et al., 2009). In mammalian cells, aggresomes
are ubiquitylated, highly dynamic and easily accessible to the
UPS (Johnston et al., 1998). They are formed from smaller aggre-
gates, which are actively transported to the centrosome via the
microtubule cytoskeleton (Johnston et al., 1998). Both the N17
fragment and the proline-rich domain of huntingtin are required
for aggresome formation in yeast (Wang et al., 2009). Alterna-
tively, polyQ aggregates (it is unclear whether 103Q or 103QP has
been used) could be transported to perivacuolar inclusions, called
“insoluble protein deposits” (IPOD) (Kaganovich et al., 2008).
IPODs are non-ubiquitylated insoluble protein aggregates cov-
ered by the ubiquitin-like autophagy protein Atg8 (Kaganovich
et al., 2008). Therefore, it is tempting to speculate that polyQ
aggregates in perivacuolar inclusions are substrates of autophagy,
whereas polyQ aggregates in aggresomes are primarily substrates
of the UPS.
PolyQ aggregates could be ubiquitylated (96QP) (Lu et al.,
2014), and physically interacted with proteins of the UPS, includ-
ing proteasomal subunits (103QP, 96QP) (Wang et al., 2009;
Park et al., 2013). Consistently, polyQ aggregate clearance (103Q)
was improved in a yeast strain with elevated UPS capacities
(1ubr2), confirming that polyQ aggregates are substrates of the
UPS (Kruegel et al., 2011). However, the degradation of ubiqui-
tylated polyQ was not limited to the UPS but could also occur
by ubiquitin-dependent autophagy (Lu et al., 2014). Here, polyQ
(96QP) was ubiquitylated by the E3 ligase Rsp5, and ubiquity-
lated polyQ was recognized by the ubiquitin-Atg8 adaptor pro-
tein Cue5, enabling the targeting of polyQ aggregates (96QP)
to the vacuole for their degradation (Lu et al., 2014). In sum,
ubiquitylated polyQ aggregates are degraded via the UPS, and
ubiquitin-dependent autophagy.
Yeast strains with mutations affecting the formation of endo-
cytic vesicles demonstrated decreased aggregation of polyQ (47Q,
103Q, 103QP) (Meriin et al., 2007). In contrast, lack of pro-
teins which are pivotal for later steps of endocytosis increased
polyQ aggregation (103Q), and when present these proteins co-
localized with polyQ aggregates (103Q) (Meriin et al., 2007).
These data suggest that these ubiquitin-controlled vesicular pro-
cesses are involved in the formation of polyQ aggregates (Meriin
et al., 2007). However, whether they are also involved in the
degradation of polyQ remains elusive.
Frontiers in Molecular Neuroscience | www.frontiersin.org 7 March 2015 | Volume 8 | Article 8
Braun Yeast models expressing neurotoxic proteins
PolyQ Expression Leads to Impairment of Specific
Branches of the UPS Pathway in Yeast
PolyQ expression inhibits the UPS. In the presence of polyQ,
increased cellular levels of polyubiquitylated proteins were
observed (with 103Q but not with 103QP) (Duennwald and
Lindquist, 2008), genes involved in ubiquitin cycle and protein
ubiquitylation were up-regulated (with 103Q) (Giorgini et al.,
2008; Tauber et al., 2011), and the degradation of cytosolic and
ER-associated proteins were impaired (with 103Q but not with
103QP) (Duennwald and Lindquist, 2008). Notably, the polyQ-
dependent UPS impairment is substrate specific. Upon polyQ
expression (103Q), the degradation of cytosolic ubiquitin-fusion
degradation (UFD) substrates (Ub-P-LacZ) was more affected
than the degradation of cytosolic substrates of the N-end rule
pathway (Ub-R-LacZ) (Duennwald and Lindquist, 2008). Con-
sistently, the degradation of ER-associated proteins via ERAD,
which shares many components with the UFD pathway, was
drastically affected upon polyQ expression (103Q) (Duennwald
and Lindquist, 2008). Here, the degradation of the ER lumi-
nal misfolded variant of the carboxypeptidase Y (CPY∗) was
impaired, as well as the degradation of the misfolded ER mem-
brane protein sec61-2, and others (Duennwald and Lindquist,
2008). PolyQ (both 103Q and 103QP) physically interacted with
the AAA-ATPase Cdc48 and its co-factors Ufd1 and Npl4, which
are pivotally involved in UFD and ERAD (Duennwald and
Lindquist, 2008; Wang et al., 2009). It has been proposed that
sequestration of the Cdc48-Ufd1/Npl4 complex by polyQ (103Q)
is the cause for the specific impairment of the UFD and ERAD
pathways, culminating in ER stress and UPR induction (Duen-
nwald and Lindquist, 2008). Notably, the interaction of polyQ
(103QP) with the Cdc48-Ufd1/Npl4 complex was essential for
the formation of the polyQ-containing aggresomes (Wang et al.,
2009). The formation of these aggresomes is believed to be a pro-
tective cellular mechanism to prevent the evenly spread of mis-
folded proteins within a cell (Johnston et al., 1998). Therefore,
the interaction of the Cdc48-Ufd1/Npl4 complex with polyQ
might be both protective (at least for 103QP) and detrimental (for
103Q); it prevents from the accumulation of misfolded polyQ but
promotes specific dysfunction of the UFD and ERAD pathways.
Expression of polyQ containing the proline-rich domain
(97QP) can also lead to UPS dysfunction via an alternative mech-
anism, which is based on the sequestration of chaperones. PolyQ
(97QP) inhibited the UPS-mediated degradation of themisfolded
cytosolic variant of carboxypeptidase Y (1ssCPY*) lacking the
signaling sequence (ss) for entering the secretory pathway (Park
et al., 2013). Upon polyQ expression (97QP), the steady-state
levels and the turnover rates of 1ssCPY∗ were increased and
delayed, respectively (Park et al., 2013). PolyQ-triggered (97QP)
UPS inhibition was not due to direct interference with protea-
somal function, because the ubiquitin-independent proteasomal
degradation of ornithine decarboxylase was not affected by polyQ
expression (Park et al., 2013). UPS dysfunction could also not be
explained by interference of polyQ (97QP) with the ubiquityla-
tion of 1ssCPY* prior its proteasomal degradation (Park et al.,
2013). Instead, polyQ (97QP) interfered with the transfer of the
misfolded protein to the proteasome, prior proteasomal degra-
dation, which surprisingly took place in the nucleus (Park et al.,
2013). The nuclear transfer of misfolded 1ssCPY∗ was done by
binding to the type II Hsp40 chaperone Sis1, which shuttles into
the nucleus, and polyQ (97QP) interfered with this process by
sequestering Sis1 in the cytosol (Park et al., 2013). Consistently,
Sis1 overexpression restored the degradation of 1ssCPY∗ in the
presence of polyQ. Thus, polyQ (both 103Q and 97QP) inter-
feres with the proteasome-dependent degradation of proteins in
the nucleus and the cytosol, by sequestering the Sis1 chaper-
one (for 97QP) and the Cdc48-Ufd1/Npl4 complex (for 103Q),
respectively.
Whether polyQ interferes with autophagy and protein degra-
dation based on ubiquitin-controlled vesicular transport remains
to be determined. Since polyQ aggregates (103Q) impaired endo-
cytosis in yeast (Meriin et al., 2003, 2007), it is tempting to spec-
ulate that polyQ aggregates (103Q) also affect these vesicle-based
protein degradation pathways.
PolyQ Expression in Yeast Triggers Mitochondrial
Dysfunction and ER Stress, which is Modulated by
Specific UPS Activities
PolyQ constructs encoding 103 glutamine residues (103Q) effi-
ciently triggered growth deficits and morphological markers of
apoptosis in yeast (Meriin et al., 2002; Duennwald et al., 2006a;
Sokolov et al., 2006; Solans et al., 2006). In contrast, polyQ con-
structs encoding 25 glutamine residues (25Q) remained non-
toxic, and the constructs with intermediate polyQ lengths showed
intermediate cytotoxicity (Meriin et al., 2002; Duennwald et al.,
2006a; Sokolov et al., 2006; Solans et al., 2006; Ocampo et al.,
2010). Besides the number of glutamine expansions, the cyto-
toxicity of polyQ strongly depended on the proline-rich domain
flanking the polyQ stretch (Duennwald et al., 2006b). PolyQ
(103QP) remained non-toxic, whereas polyQ lacking the proline-
rich region (103Q) induced cytotoxicity (growth deficits) (Duen-
nwald et al., 2006b). In this context, the presence of the prion
conformation of the yeast protein Rnq1 was a prerequisite for
polyQ-triggered cytotoxicity (103Q), and the presence of other
endogenous yeast proteins with glutamine repeats also influenced
polyQ-triggered cytotoxicity (103Q) (Duennwald et al., 2006a).
Thus, polyQ-triggered cytotoxicity depends on the length of the
glutamine repeats, the absence or presence of the proline-rich
domain, and the cellular protein interaction network.
Cytotoxic polyQ (103Q) physically interacted with mito-
chondria and triggers critical mitochondrial dysfunction (Solans
et al., 2006; Ocampo et al., 2010). PolyQ expression (103Q but
not 103QP) also induced ER stress leading to UPR (Duen-
nwald and Lindquist, 2008), and has also been proposed to
lead to lethal impairment of cell cycle progression (Bocharova
et al., 2008, 2009). ER and cell cycle impairments are believed
to be consequences of the impairment of specific branches
of the UPS pathway by polyQ expression (103Q), includ-
ing the ERAD and anaphase promoting complex (APC) path-
ways (Bocharova et al., 2008, 2009; Duennwald and Lindquist,
2008). The mitochondrion-associated protein degradation path-
way (MAD) shares pivotal components with the ERAD pathway
(Heo et al., 2010; Taylor and Rutter, 2011). Therefore, it is tempt-
ing to speculate that polyQ expression (103Q) also impairs MAD,
contributing to the observed mitochondrial damage.
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PolyQ-triggered cytotoxicity was increased by genetic impair-
ment of the ERAD and UPR pathways and by application of ER
stress (for 103Q but not for 103QP) (Duennwald and Lindquist,
2008). In contrast, promoting ERAD by expression of Npl4 and
Ufd1, which are pivotally involved in ERAD, or constitutive
activation of the UPR suppressed polyQ-triggered cytotoxicity
(103Q) (Duennwald and Lindquist, 2008). These data are in line
with the idea that ERADdysfunction by polyQ expression (103Q)
is critical in the execution of cytotoxicity and cell death. Deletion
of the APC substrate ASE1 relieved polyQ-triggered cytotoxic-
ity (103Q), suggesting that preventing the accumulation of Ase1
upon dysfunction of the APC pathway is beneficial (Bocharova
et al., 2008). Expression of polyQ flanked by the proline-rich
domain (96QP), which is non-toxic under normal conditions,
became cytotoxic upon accumulation of the UPS model sub-
strate 1ssCPY∗ and could be relieved upon Sis1 overexpression
(Park et al., 2013). Genetic inactivation of ubiquitin-dependent
autophagy (e.g., rsp5-2, 1cue5) also induced cytotoxicity upon
polyQ expression (96QP) (Lu et al., 2014). These data suggest that
besides ERAD and APC pathways, the Sis1-dependent protein
degradation and the ubiquitin-dependent autophagy are pivotal
in the modulation of polyQ-triggered cytotoxicity in yeast.
Yeast PolyQ Models are Highly Useful to Elucidate
the Role of Diverse Ubiquitin-Related Protein
Degradation Pathways in Modulating Cytotoxicity
and Neuronal Cell Death
PolyQ expression in yeast leads to aggregation, and aggre-
gates can be allocated to distinct cellular compartments, includ-
ing aggresomes and perivacuolar inclusions (IPOD) (Figure 2,
Table 1). Aggregated polyQ is a substrate of the UPS and
autophagy. Besides its role of a substrate of protein degradation,
polyQ impairs the UPS (especially ERAD), and also affects proper
function of vesicular transport (more specifically endocytosis).
This leads to ER stress, mitochondrial dysfunction, and cell death.
All these features depend on the length of the polyQ stretch, the
absence (or presence) of the N-terminal part (N17 fragment) and
the proline-rich domain, respectively, and the cellular protein
interaction network.
The data obtained in yeast HD models have been very helpful
for a better understanding of polyQ-triggered effects in higher
model systems, as well as in humans. For instance, the alloca-
tion of different aggregates into distinct cellular compartments
(aggresomes and IPOD, respectively) was conserved from yeast
to mammalians (Johnston et al., 1998; Kaganovich et al., 2008;
Wang et al., 2009). As in yeast, polyQ are substrates of the UPS
and autophagy (Lu et al., 2014; Margulis and Finkbeiner, 2014;
Martin et al., 2014). PolyQ aggregates block specific branches of
the UPS (including the ERAD and the Sis1-dependent pathways)
in mammalians as in yeast (Duennwald and Lindquist, 2008;
Park et al., 2013; Margulis and Finkbeiner, 2014). Like in yeast
cells, polyQ impairs vesicle-based protein degradation, including
autophagy (Sapp et al., 1997; Aronin et al., 1999; Meriin et al.,
2003, 2007; Martin et al., 2014).
Interestingly, in cultured cells and in flies, ubiquitylation (and
sumolyation) of the N-terminal part of huntingtin (N17) at
specific residues (K6, K9, and K15) turned out to be an efficient
modulator of polyQ aggregation and neurotoxicity (Steffan et al.,
2004). Thus, distinct (poly)ubiquitylation patterns could on the
one hand dictate the fate of polyQ (e.g., aggregation and degra-
dation) and on the other hand determine its effects on ubiquitin-
dependent degradation of other cellular proteins. This issue could
further be dissected in yeast HD models.
Of specific interest is the role of p97/VCP, the ortholog of the
yeast AAA-ATPase Cdc48. As in yeast, p97/VCP and its cofactors
Npl4 and Ufd1 were sequestered by polyQ aggregates in mam-
malian cells leading to ERAD dysfunction, ER stress, and UPR
induction (Duennwald and Lindquist, 2008). Overexpression of
Npl4, Ufd1, or p97/VCP rescued from ERAD dysfunction and/or
ER stress and UPR (Duennwald and Lindquist, 2008; Leitman
et al., 2013). In C. elegans, p97/VCP was involved in the clear-
ance of detrimental polyQ aggregates (Nishikori et al., 2008).
Since p97/VCP has also been proposed to play important roles in
autophagy and apoptosis (Braun and Zischka, 2008; Krick et al.,
2010), it is tempting to speculate that the interaction of polyQ
aggregates with this protein complex is critical for the switch
from UPS and autophagy dysfunctions to neuronal cell loss.
Alzheimer’s Disease (AD)
AD is the most prevalent form of age-related dementia (Quer-
furth and Laferla, 2010). Synaptic loss and neuronal decline can
be observed in affected brain regions, including the hippocampus
and the cortex (Querfurth and Laferla, 2010). The accumulation
of extracellular senile plaques and intracellular aggregates, com-
posed of β-amyloid, and the intracellular accumulation of neu-
rofibrillary tangles comprising hyperphosphorylated variants of
the protein tau and UBB+1, the frameshift variant of ubiquitin B,
contribute to AD progression (van Leeuwen et al., 1998; Laferla
et al., 2007; Benilova et al., 2012; Mandelkow and Mandelkow,
2012).
Yeast β-Amyloid Models
Several yeast models expressing β-amyloid in the cytosol and in
the secretory pathway have been generated (Caine et al., 2007;
Treusch et al., 2011; D’Angelo et al., 2013; Matlack et al., 2014;
Mossmann et al., 2014) (Table 1). Cytosolic β-amyloid (GFP-
Aβ42 or Aβ42-GFP fusion proteins) led to moderate growth
deficits and to the induction of the heat shock response in
wild-type cells (Caine et al., 2007). Mitochondria isolated from
aging-prone yeast cells (1coa6) upon prolonged exposure to
cytosolic Aβ42 demonstrated signs of mitochondrial impair-
ment, including inhibition of mitochondrial pre-protein mat-
uration, increased ROS production, decreased mitochondrial
membrane potential and reduced oxygen consumption (Moss-
mann et al., 2014). Recent studies suggest that mitochondrial
impairment triggers UPS dysfunction and vice versa (Livnat-
Levanon et al., 2014; Maharjan et al., 2014; Segref et al., 2014;
Braun et al., 2015). Since mitochondrial and UPS dysfunction
are believed to contribute to AD progression, it is of high inter-
est, whether cytosolic Aβ42 interacts with ubiquitin-dependent
processes.
Whereas, the detrimental effects of cytosolic β-amyloid
remained moderate, β-amyloid directed to the secretory path-
way resulted in high cytotoxicity concomitant to β-amyloid
oligomerization and aggregation (Treusch et al., 2011; D’Angelo
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FIGURE 2 | Yeast model for polyQ-triggered cytotoxicity. PolyQ
monomers are very aggregation-prone forming smaller and larger
aggregates, which can be ubiquitylated (1). These aggregates can be
transported to two cellular compartments, the perivacuolar inclusion
(IPOD, non-ubiquitylated) (2) or the perinuclear aggresome (ubiquitylated)
(3). IPODs are potential substrates of autophagy (4). Aggresomes and
other ubiquitylated polyQ aggregates are substrates of the UPS (5, 6),
and of ubiquitin-dependent autophagy (via the Cue5 ubiquitin-Atg8
adaptor protein) (7). PolyQ aggregates trigger mitochondrial dysfunction
and ROS (8), as well as ER stress and UPR (9). The first was explained
by a direct detrimental physical interaction of polyQ aggregates with
mitochondria. For the latter it has been shown that polyQ aggregates
sequester the AAA-ATPase Cdc48 (10), leading to ERAD dysfunction (11).
Sequestering Cdc48 could potentially lead to MAD dysfunction (12)
(which shares many components with ERAD) and to impairment of
aggresome formation (13) (which depends on Cdc48). Ubiquitylated polyQ
aggregates inhibit the degradation of misfolded cytosolic proteins in the
nucleus via sequestering the chaperone Sis1 (14).
et al., 2013; Matlack et al., 2014). Here, β-amyloid impaired the
clathrin-mediated endocytic trafficking of a plasma membrane
receptor (which is a ubiquitin-modulated process), and expres-
sion of endocytic genes rescued β-amyloid-triggered cytotoxicity
(Treusch et al., 2011; D’Angelo et al., 2013). A genome-
wide screen for modifiers of β-amyloid-triggered cytotoxicity
identified the yeast homolog of phosphatidylinositol binding
clathrin assembly protein (PICALM), as suppressor of cytotox-
icity (Treusch et al., 2011). A screen of ∼140,000 compounds
for β-amyloid rescue in yeast identified the 8-hydroxyquinoline
clioquinol as effective in preventing β-amyloid-triggered growth
deficits via promoting β-amyloid degradation and restoring
endocytic function (Matlack et al., 2014). The outcome of these
two unbiased yeast screens validate the usefulness of yeast AD
models, because PICALM is one of the most highly validated
AD risk factors (Treusch et al., 2011), and clioquinol is effec-
tive in both mouse and C. elegans AD models (Matlack et al.,
2014).
Yeast tau Models
Yeast models expressing AD-associated tau have been gener-
ated (De Vos et al., 2011) (Table 1). Tau forms oligomers and
is hyperphosphorylated when expressed in yeast as it is in
AD patients (Vandebroek et al., 2005, 2006; Zabrocki et al.,
2005; Vanhelmont et al., 2010). Although tau expression per se
remained non-toxic in wild-type cells, it increased α-synuclein-
triggered growth deficits (Zabrocki et al., 2005). Therefore, com-
bining several AD risk factors (e.g., tau, β-amyloid, and/or
UBB+1) could lead to more effective yeast AD models. This
turned out to be necessary in mouse AD models, because muta-
tions in tau are also not very toxic in transgenic mice (Nisbet
et al., 2015). Similarly, AD-associated mutations in the β-amyloid
precursor protein (APP) or the γ-secretase components prese-
nilin 1 or 2, which are pivotally involved in β-amyloid genera-
tion from APP, do also not fully recapitulate the key pathological
events of AD (Nisbet et al., 2015). In order to mimic simultane-
ously more than one pathological aspect of AD double and triple
transgenic AD mouse models or AD patient-derived neuronal
stem-cell-derived three-dimensional culture systems have been
developed (van Tijn et al., 2012; Choi et al., 2014; Nisbet et al.,
2015).
Yeast UBB+1 Models
UBB+1-expressing yeast models have been established (Tank and
True, 2009; Verhoef et al., 2009; Dennissen et al., 2011; Krutauz
et al., 2014; Braun et al., 2015) (Table 1). As in mammalian cells,
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UBB+1 is a substrate of the UPS in yeast. It is ubiquitylated prior
proteasomal degradation and truncated by the DUB Yuh1 (or
mammalian ubiquitin carboxy-terminal hydrolase UCH-L3) (De
Vrij et al., 2001; van Tijn et al., 2007, 2010; Tank and True, 2009;
Verhoef et al., 2009; Dennissen et al., 2011; Braun et al., 2015).
Accumulation of UBB+1 impairs the UPS in yeast and mam-
malian cells, culminating in the accumulation of polyubiquity-
lated proteins. In both cases, the degradation of UFD substrates
(e.g., Ub-G76V-GFP, Ub-P-LacZ), and of N-end rule substrates
(e.g., Ub-R-GFP, Ub-R-LacZ) was significantly reduced (Lindsten
et al., 2002; van Tijn et al., 2007; Tank and True, 2009; Braun et al.,
2015). The inhibitory effect of UBB+1 on the UPS is at least par-
tially due to inhibition of DUBs, especially Ubp6/USP14, which is
associated with the 26S proteasome and involved in the disassem-
bly of polyubiquitin tags from substrate proteins (Krutauz et al.,
2014).
Despite of the UBB+1-triggered UPS impairment, both yeast
and mammalian cells can tolerate UBB+1 without marked signs
of cytotoxicity (Hope et al., 2003; van Tijn et al., 2007, 2012;
Tank and True, 2009; Yim et al., 2014), and in some cases
UBB+1 expression was even protective when mammalian cells
were treated with chemicals inducing oxidative stress (Hope et al.,
2003; Yim et al., 2014). Consistently, transgenic expression of
UBB+1 in mice failed to cause overt neurodegeneration although
it did affect spatial reference memory and caused a central dys-
function of respiratory regulation (Fischer et al., 2009; van Tijn
et al., 2011; Irmler et al., 2012). In contrast, prolonged expression
of high levels of UBB+1 induced cell death and pivotal mito-
chondrial impairment in neuronal cells and in yeast (De Vrij
et al., 2001; Tan et al., 2007; Braun et al., 2015). In yeast the
UBB+1-triggered cell death could be prevented by specifically
promoting the UPS activity at mitochondria (mitochondrion-
associated degradation, MAD), which protected cells from mito-
chondrial impairment but did not alter the steady-state levels
of UBB+1 (Braun et al., 2015). The accumulation of UBB+1
increased the cytotoxicity of polyQ (103Q) in yeast (Tank and
True, 2009), which is highly comparable to mammalian systems,
where UBB+1 expression accelerates cell death in transgenic HD
mouse models (de Pril et al., 2004, 2007, 2010). Thus, on the one
hand UBB+1 is a neurotoxic protein by itself, whose cytotoxicity
depends both on the cellular UPS capacity and on mitochondrial
(dys)function. On the other hand UBB+1 is putatively a potent
modifier of cytotoxicity of other misfolded neurotoxic proteins.
Especially when combined with further AD risk factors, includ-
ing β-amyloid and tau, the yeast UBB+1 model could be very
valuable for elucidating the molecular connections among AD
risk factors, UPS (dys)function, mitochondrial activity, and cell
survival.
Amyotrophic Lateral Sclerosis (ALS)
ALS is a frequent degenerative motor neuron disease, resulting in
muscle weakness and wasting (Andersen and Al-Chalabi, 2011).
Among the most common ALS-associated genes are TARDBP,
and FUS, encoding the RNA-binding proteins TDP-43 and
FUS/TLS (Andersen and Al-Chalabi, 2011). ALS-associated vari-
ants of these proteins demonstrate mislocalization and/or a high
tendency for aggregation, and these aggregates are ubiquitylated
(Andersen and Al-Chalabi, 2011; Da Cruz and Cleveland, 2011).
Yeast models expressing ALS-associated wild-type and mutant
TDP-43 and FUS/TLS have been established to further analyze
the detrimental roles of these proteins on cell survival (Bastow
et al., 2011).
TDP-43 and FUS/TLS efficiently form cytoplasmic aggre-
gates when expressed in yeast cells triggering cytotoxicity and
cell death (Johnson et al., 2008; Braun et al., 2011; Kryn-
dushkin et al., 2011; Sun et al., 2011) (Table 1). It is very lit-
tle known via which pathways these neurotoxic proteins and
their aggregates are degraded in yeast, whether these proteins
impair ubiquitin-modulated protein degradation, and whether
the activities of ubiquitin-modulated proteolysis pivotally affect
their cytotoxicity. In the case of TDP-43, a temperature-sensitive
variant of the AAA-ATPase Cdc48 was found as an enhancer
of TDP-43-triggered cytotoxicity (growth deficits) (Armakola
et al., 2012). Promoting vesicular trafficking (ER -> Golgi) by
treating TDP-43-expressing yeast cells with NAB relieved TDP-
43-triggered cytotoxicity (Tardiff et al., 2012, 2013). Thus, the
activities of ubiquitin-modulated vesicular transport and Cdc48-
dependent cellular processes may be pivotal in modulating TDP-
43-triggered cytotoxicity in yeast and neurons. Cdc48 and its
mammalian homolog p97/VCP are involved in many differ-
ent ubiquitin-modulated processes, including ERAD, MAD, and
vesicular transport, such as endocytosis, and autophagy (Bug and
Meyer, 2012). Indeed, mutations in p97/VCP lead to cytoplas-
mic TDP-43 aggregation and cell death in neurons of transgenic
mice and flies (Gitcho et al., 2009; Johnson et al., 2010; Ritson
et al., 2010; Rodriguez-Ortiz et al., 2013). Yeast TDP-43 mod-
els could help to further discriminate the role of the distinct
Cdc48/p97/VCP pathways in modulating cell death and neuronal
loss.
Conclusions and Outlook
In yeast models expressing neurotoxic proteins, these proteins
are on the one hand substrates of distinct protein degrada-
tion pathways, and on the other hand the trigger for their
impairment. Consistently, the activities of the UPS, autophagy,
and other ubiquitin-controlled vesicle-based protein degradation
pathways are pivotal for the cytotoxicity of neurotoxic proteins.
Best described for yeast PD and HDmodels, these findings could
be confirmed in other neurotoxic model systems, confirming that
yeast models expressing neurotoxic proteins are very helpful in
elucidating novel paradigms of pathobiology in neurodegener-
ative disorders. It is very likely, that yeast models for AD (β-
amyloid, tau, UBB+1), and ALS (e.g., TDP-43, FUS/TLS), will
lead to the identification of further ubiquitin-regulated protein
degradation pathways that potentially underlie neuronal dys-
function and cell loss. In this respect, the easy and fast combi-
nation of different neurotoxic proteins in one yeast model (e.g.,
different AD-associated proteins) could be a very straightforward
approach.
The role of free ubiquitin homeostasis has been largely unat-
tended when analyzing the effects of ubiquitylated neurotoxic
proteins and ubiquitin-dependent protein degradation on neu-
ronal survival. For instance, loss of free ubiquitin was found in
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schizophrenia (Rubio et al., 2013), and down-regulation of free
ubiquitin was determined to be causative for p53 accumulation
and apoptosis in hippocampal neurons from rats (Tan et al.,
2000). In contrast, free ubiquitin levels increase in cancer cells,
which turned out to be pivotal for cell growth (Oh et al.,
2013). Consistently, high levels of free ubiquitin confers resis-
tance to inhibitors of protein translation in yeast (Hanna et al.,
2003). Modulating free ubiquitin levels in yeast models express-
ing human neurotoxic proteins could address the role of free
ubiquitin homeostasis on the degradation and the cytotoxicity of
these proteins.
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